SAREPTA THERAPEUTICS, INC. Finite-Lived License Agreements, Gross
SAREPTA THERAPEUTICS, INC. (SRPT) had Finite-Lived License Agreements, Gross of $1.00 million as of 2016-09-30, per its 10-Q filed 2016-11-07.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Finite-Lived, before Accumulated Amortization
us-gaap:FiniteLivedLicenseAgreementsGross · last filed 2016-11-07
- 2016-09-30: Finite-Lived License Agreements, Gross $1.00M.
| Period end | Finite-Lived License Agreements, Gross |
|---|---|
| 2016-09-30 | $1.00M 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |